Health Canada updates on vaccines, treatments for Covid-19

eAwazMedicine

Product description Brand name COMIRNATY that has been approved recently by Health Canada Company name BioNTech Manufacturing GmbH Ingredient mRNA encoding SARS-CoV-2 spike protein, 5’ [m27,3’-OGppp(m12’-O)ApG] cap, 110-nucleotide 3′ poly(A) tail with a 10-nucleotide linker sequence. This product (COMIRNATY) includes an update to the antigen composition (variant Omicron KP.2) and replaces COMIRNATY Omicron XBB.1.5 (raxtozinameran).

Health Canada authorizes Pfizer-BioNTech Covid-19 vaccine targeting Omicron XBB.1.5 

eAwazMedicine

Ottawa – Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant for individuals six months of age and older. Health Canada received Pfizer-BioNTech’s submission on June 29, 2023. After a thorough and independent review of the evidence, Health Canada has determined that the vaccine meets the Department’s stringent safety, efficacy and quality requirements. …